Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Reynes

Showing results (181-190 of 200) with videos related to

Pageof 20
Sort By:
Clinical and Translational Allergy|December 9, 2020
Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategiesJean Bousquet, Jean-Paul Cristol, Wienczyslawa Czarlewski, et al.
Antimicrobial Agents and Chemotherapy|June 10, 2010
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism studyPatricia Recordon-Pinson, Cathia Soulié, Philippe Flandre, et al.
The Lancet. Infectious Diseases|February 22, 2015
Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trialAntoine Chéret, Georges Nembot, Adeline Mélard, et al.
The Journal of Allergy and Clinical Immunology|July 16, 2022
Angiotensin II induces reactive oxygen species, DNA damage, and T-cell apoptosis in severe COVID-19Lucy Kundura, Sandrine Gimenez, Renaud Cezar, et al.
Molecular Ecology|September 4, 2022
Does exposure to different menstrual products affect the vaginal environment?Nicolas Tessandier, Ilkay Başak Uysal, Baptiste Elie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2019
Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Dat'AIDS Cohort StudyMarie Demontès, Sabrina Eymard Duvernay, Clotilde Allavena, et al.
The Lancet. Infectious Diseases|September 22, 2011
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trialJoseph J Eron, Jürgen K Rockstroh, Jacques Reynes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority StudyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
AIDS Patient Care and Stds|August 23, 2007
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretroviralsJacques Reynes, Keikawus Arastéh, Bonaventura Clotet, et al.
Scientific Reports|February 19, 2022
Performances of rapid and connected salivary RT-LAMP diagnostic test for SARS-CoV-2 infection in ambulatory screeningFrancisco Santos Schneider, Laurence Molina, Marie-Christine Picot, et al.
Pageof 20

Showing results (181-190 of 200) with videos related to

Sort By:
Pageof 20
Clinical and Translational Allergy|December 9, 2020
Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategiesJean Bousquet, Jean-Paul Cristol, Wienczyslawa Czarlewski, et al.
Antimicrobial Agents and Chemotherapy|June 10, 2010
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism studyPatricia Recordon-Pinson, Cathia Soulié, Philippe Flandre, et al.
The Lancet. Infectious Diseases|February 22, 2015
Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trialAntoine Chéret, Georges Nembot, Adeline Mélard, et al.
The Journal of Allergy and Clinical Immunology|July 16, 2022
Angiotensin II induces reactive oxygen species, DNA damage, and T-cell apoptosis in severe COVID-19Lucy Kundura, Sandrine Gimenez, Renaud Cezar, et al.
Molecular Ecology|September 4, 2022
Does exposure to different menstrual products affect the vaginal environment?Nicolas Tessandier, Ilkay Başak Uysal, Baptiste Elie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2019
Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Dat'AIDS Cohort StudyMarie Demontès, Sabrina Eymard Duvernay, Clotilde Allavena, et al.
The Lancet. Infectious Diseases|September 22, 2011
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trialJoseph J Eron, Jürgen K Rockstroh, Jacques Reynes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority StudyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
AIDS Patient Care and Stds|August 23, 2007
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretroviralsJacques Reynes, Keikawus Arastéh, Bonaventura Clotet, et al.
Scientific Reports|February 19, 2022
Performances of rapid and connected salivary RT-LAMP diagnostic test for SARS-CoV-2 infection in ambulatory screeningFrancisco Santos Schneider, Laurence Molina, Marie-Christine Picot, et al.
Pageof 20